JPRN-UMIN000041037已完成Unknown
Open-label, randomized, parallel group trial to evaluate the effect on work productivity by patient education and strengthening exercise therapy in patients with chronic low back pain - Open-label, randomized, parallel group trial to evaluate the effect on work productivity by patient education and strengthening exercise therapy in patients with chronic low back pain
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 入组人数
- 101
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 64years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients who have the Red flags 2. Patient who are pregnant or wish to become pregnant 3. Patients who have radiculopathy 4. Patients who have strong opioids
研究者
相似试验
进行中（未招募）
1 期
A study to test whether BI 685509 alone or in combination with empagliflozin helps people with liver cirrhosis caused by viral hepatitis or non-alcoholic steatohepatitis (NASH) who have high blood pressure in the portal vein (main vessel going to the liver)portal hypertensionMedDRA version: 20.1Level: PTClassification code 10036200Term: Portal hypertensionSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2021-005171-40-ATBoehringer-Ingelheim RCV GmbH & Co KG80
进行中（未招募）
1 期
A study to test whether BI 685509 alone or in combination with empagliflozin helps people with liver cirrhosis caused by viral hepatitis or non-alcoholic steatohepatitis (NASH) who have high blood pressure in the portal vein (main vessel going to the liver)portal hypertensionMedDRA version: 20.1Level: PTClassification code 10036200Term: Portal hypertensionSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2021-005171-40-DKBoehringer Ingelheim B. V.80
进行中（未招募）
1 期
A study to test whether BI 685509 alone or in combination with empagliflozin helps people with liver cirrhosis caused by viral hepatitis or non-alcoholic steatohepatitis (NASH) who have high blood pressure in the portal vein (main vessel going to the liver)portal hypertensionMedDRA version: 20.1Level: PTClassification code 10036200Term: Portal hypertensionSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2021-005171-40-DEBoehringer Ingelheim Pharma GmbH & Co. KG - Clinical Research Germany80
招募中
2 期
A study to test whether BI 685509 alone or in combination with empagliflozin helps people with liver cirrhosis caused by viral hepatitis or non-alcoholic steatohepatitis (NASH) who have high blood pressure in the portal vein (main vessel going to the liver)Patients with CSPH in compensated cirrhosis due to HBV, HCV, and NASH with or without T2DMJPRN-jRCT2031220376Kutsunai Mitsuru5
尚未招募
2 期
Randomised, open-label and parallel group trial to investigate the effects of oral BI 685509 alone or in combination with empagliflozin on portal hypertension after 8 weeks treatment in patients with clinically significant portal hypertension (CSPH) in compensated cirrhosis.Clinical significant portal hypertension (CSPH)high blood pressure in portal vein10057166NL-OMON53952Boehringer Ingelheim5